Epistaxis Secondary to Panitumumab in a Patient With Colon Cancer.

Epistaxis secondary to panitumumab in a patient with colon cancer.

Filed under: Drug and Alcohol Rehabilitation

Anticancer Res. 2012 Nov; 32(11): 4983-5
Kornreich DA, Saif MW

Epidermal growth factor receptor inhibitors (EGFRIs) have become an integral part of therapy for many types of solid malignancy, including colorectal cancer. The drug class has proven to be effective without causing many of the side-effects associated with chemotherapy or other growth factor receptor inhibitors. Epistaxis, a common side-effect of Vascular Endothelial Growth Factor inhibitors, is rarely noted with EGFRIs. We report on one patient, a 51-year-old man with metastatic colon cancer, who developed severe epistaxis with the use of panitumumab. We discuss the other reported cases of EGFRIs causing epistaxis and hypothesize on possible mechanisms by which this drug class might cause mucosal bleeding.
HubMed – drug

 

Epigallocatechin Gallate Acts Synergistically in Combination with Cisplatin and Designed trans-palladiums in Ovarian Cancer Cells.

Filed under: Drug and Alcohol Rehabilitation

Anticancer Res. 2012 Nov; 32(11): 4851-60
Mazumder ME, Beale P, Chan C, Yu JQ, Huq F

In this study, synergism in activity from the sequenced combinations of three trans-palladiums (denoted as TH5, TH6 and TH7) with green tea polyphenol (-)-epigallocatechin-3-gallate (EGCG), as well as that with cisplatin, was investigated in a number of human ovarian tumour models as a function of sequence of administration. Cellular accumulation of platinum and palladium, and the levels of platinum-DNA and palladium-DNA binding were also determined for the 0/4 h and 0/0 h sequences of administration. The results of the study show that co-administration of cisplatin with EGCG (0/0 h) produces weak synergism in both cisplatin-sensitive (A2780) and cisplatin-resistant (A2780(cisR)) cell lines whereas (0/4 h) administration produces pronounced synergism in both. In contrast, bolus administration of EGCG with TH5, TH6 and TH7 produces marked antagonism except that with TH5, in the A2780(cisR) cell line, where a mild synergism is observed. In the case of TH5, TH6 and TH7, administration of drugs with a time gap (0/4 h or 4/0 h combinations) produces sequence-dependent synergism in both A2780 and A2780(cisR) cell lines, whereas in the case of cisplatin, marked antagonism is observed with the 4/0 h sequence of administration in the A2780 cell line. Whereas the highly synergistic 0/4 h sequence of combination of cisplatin with EGCG is found to be associated with pronounced cellular accumulation of platinum and a high level of platinum-DNA binding, no such clear trend can be seen for any of the combinations of TH5, TH6 and TH7 with EGCG. The results of the present study provide support to the idea that sequenced combinations of platinum drugs and tumour-active palladium compounds with selected phytochemicals such as EGCG may provide a means of overcoming drug resistance.
HubMed – drug

 

Studies on combination of platinum drugs Cisplatin and oxaliplatin with phytochemicals anethole and curcumin in ovarian tumour models.

Filed under: Drug and Alcohol Rehabilitation

Anticancer Res. 2012 Nov; 32(11): 4843-50
Nessa MU, Beale P, Chan C, Yu JQ, Huq F

Chemopreventative phytochemicals having antitumour and antioxidant properties can overcome problems of chemoresistance and nonspecific toxicity towards normal cells that are associated with platinum-based chemotherapy against cancer. These agents exert their effects by bringing into play numerous cellular proteins that in turn affect multiple steps in pathways leading to tumourigenesis. In this study, combinations of two cytotoxic phytochemicals anethole and curcumin were applied in binary combination with platinum drugs cisplatin and oxaliplatin to three epithelial ovarian cancer cell lines: A2780 (parent), A2780(cisR) (cisplatin-resistant) and A2780(ZD0473R) (ZD0473-resistant). Cell viability was quantified using the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) reduction assay and the combined drug action was analyzed based on the equations derived by Chou and Talalay (1984). Greatest synergism was observed when the phytochemical was added first followed by the platinum drug 2 h later and additiveness to antagonism in combined drug action was observed when the two compounds were administered as a bolus. If confirmed in vivo, the appropriate sequenced combinations of platinum with the phytochemicals may provide a means of overcoming drug resistance.
HubMed – drug

 

More Drug And Alcohol Rehabilitation Information…